Sputnik V vaccine produced in large bioreactors for mass output, RDIF says
He noted that the production of Sputnik V started in other countries, for instance, in India, South Korea, Brazil and China
MOSCOW, December 17. /TASS/. Production of Sputnik V has switched to large bioreactors which allows to set up a mass output of the vaccine, Head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev said on Thursday in an interview with the Russia-24 TV channel.
"The vaccine production has already shifted to large bioreactors which, accordingly, allow to arrange a mass [output]," he said.
Read also
He noted that the production of Sputnik V started in other countries, for instance, in India, South Korea, Brazil and China. "We actually use their industrial capacities in order to satisfy demand on external markets," he added.